- |||||||||| Avastin (bevacizumab) / Roche
Trial initiation date: Optune (clinicaltrials.gov) - Mar 29, 2017 P2, N=85, Not yet recruiting, The patient experienced a rapid, radiographic response, demonstrating the potential for LOXO-101 to provide benefit for IFS harboring NTRK gene fusions. Initiation date: Oct 2016 --> Apr 2017
- |||||||||| sunitinib / Generic mfg., Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open, Trial initiation date, Trial primary completion date, Stroma: Ph II CABOGIST in GIST (clinicaltrials.gov) - Mar 28, 2017 P2, N=50, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Feb 2017 | Trial primary completion date: Jan 2017 --> Aug 2019
- |||||||||| Onureg (azacitidine oral) / BMS, Istodax (romidepsin) / Astellas, BMS
Trial completion, Combination therapy, Metastases: A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma (clinicaltrials.gov) - Mar 24, 2017 P1, N=18, Completed, Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed
- |||||||||| Trial primary completion date: A Study of Lymphoseek (clinicaltrials.gov) - Mar 24, 2017
P2, N=32, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Dec 2020 --> Sep 2017
- |||||||||| Stivarga (regorafenib) / Bayer, sunitinib / Generic mfg.
Enrollment closed, Trial primary completion date, Stroma, Metastases: Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST (clinicaltrials.gov) - Mar 23, 2017 P1, N=35, Active, not recruiting, The authors recommend an individualized approach with careful multidisciplinary decision making, and the patient should be informed about the morbidity of en bloc surgery when considering MPNST resection. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2016
- |||||||||| Mepact (mifamurtide) / Takeda
Trial completion, Trial primary completion date, Metastases: A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) (clinicaltrials.gov) - Mar 22, 2017 P2, N=8, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Nov 2016
- |||||||||| Trial completion, Trial primary completion date: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=120, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2013
- |||||||||| Trial primary completion date: A Study of Lymphoseek (clinicaltrials.gov) - Mar 22, 2017
P2, N=32, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jul 2018 --> Dec 2020
- |||||||||| linsitinib (ASP7487) / Sling Therap
Trial completion, Trial primary completion date, Metastases: LINES: Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma (clinicaltrials.gov) - Mar 22, 2017 P2, N=40, Completed, Trial primary completion date: Sep 2016 --> Jul 2017 Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Imfinzi (durvalumab) / AstraZeneca
New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: TRAMUNE: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. (clinicaltrials.gov) - Mar 21, 2017 P1, N=50, Not yet recruiting,
- |||||||||| Journal: Management of desmoplastic small round cell tumor. (Pubmed Central) - Mar 19, 2017
With this challenging disease, multidisciplinary therapy, including aggressive surgery, is warranted. This review will address DSRCT biology and treatment options and discuss outcomes.
- |||||||||| timolol oral / Generic mfg.
Journal: Myeloid Sarcoma in the Orbit. (Pubmed Central) - Mar 17, 2017 [J Pediatr Ophthalmol Strabismus. 2016;53:e64-e68.].
|